APUS
Apimeds Pharmaceuticals US, Inc.
Key Financials
Net Income
$-6001137
↓ 331.7%
EPS (Diluted)
$-0.55
↓ 205.6%
Total Liabilities
$10.8M
↑ 690.3%
Shareholders' Equity
$153.3M
↑ 11391.2%
Cash & Equivalents
$1.6M
↑ 47270.6%
Operating Income
$-11912562
↓ 834.2%
Total Assets
$164.2M
↑ 1257338.4%
Operating Cash Flow
$-8925777.00
↓ 1116.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/1/2026 | View on SEC |
| 8-K | 9/29/2026 | View on SEC |
| 8-K | 9/23/2026 | View on SEC |
| 8-K | 9/11/2026 | View on SEC |
| 8-K | 8/21/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 8-K | 7/13/2026 | View on SEC |
| 10-Q | 5/26/2026 | View on SEC |
| NT 10-Q | 5/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | APUS |
| Company Name | Apimeds Pharmaceuticals US, Inc. |
| CIK | 1894525 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 848-201-5010 |